Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10277591 | 1.00 | PDE10A (0.68) | PDE10A | |
| SCHEMBL10309441 | 0.81 | PDE10A (1.00) | PDE10A | |
| SCHEMBL15023843 | 0.74 | PDE10A (0.44) | PDE10A | |
| SCHEMBL15023842 | 0.74 | PDE10A (0.44) | PDE10A | |
| SCHEMBL10277462 | 0.74 | PDE10A (0.50) | PDE10A | |
| SCHEMBL15024112 | 0.73 | PDE10A (0.56) | PDE10A | |
| SCHEMBL15024111 | 0.73 | PDE10A (0.56) | PDE10A | |
| SCHEMBL15033532 | 0.73 | PDE10A (0.45) | PDE10A | |
| SCHEMBL7518218 | 0.73 | PDE10A (0.46) | PDE10A | |
| SCHEMBL7518208 | 0.73 | PDE10A (0.46) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3210984-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| EP-3210984-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3210984-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210984-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2663565-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2012096929-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885 |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885 |
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | PDE3A, PDE2A, PDE5A | PDE10A 5/4885 |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | PDE10A 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.